Agent for promoting corneal endothelial cell adhesion
View Patent ↗The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.
1 . A method for treatment of a corneal endothelial dysfunction caused by increased intraocular pressure, comprising (i) identifying a subject currently suffering from the corneal endothelial dysfunction and (ii) administering an effective amount of a Rho kinase inhibitor to an eye of the subject to treat the corneal endothelial dysfunction in the eye of the subject.
2 . The method according to claim 1 , wherein the Rho kinase inhibitor is at least one selected from the group consisting of (+)-trans-4-(1-aminoethyl)-1-(4-pyridylcarbamoyl)cyclohexane, 1-(5-isoquinolinesulfonyl)homopiperazine, and pharmacologically acceptable salts thereof.
3 . The method according to claim 1 , wherein the eye is a human eye.
4 . The method according to claim 1 , comprising administering an effective amount of a Rho kinase inhibitor in the form of an intracameral injection or intraocular perfusion fluid.
5 . The method according to claim 2 , wherein the Rho kinase inhibitor is (+)-trans-4-(1-aminoethyl)-1-(4-pyridylcarbamoyl)cyclohexane or a pharmacologically acceptable salt thereof.
6 . The method according to claim 5 , comprising administering an effective amount of a Rho kinase inhibitor in the form of an intracameral injection or intraocular perfusion fluid.
7 . The method according to claim 5 , wherein the eye is a human eye.
8 . The method according to claim 7 , comprising administering an effective amount of a Rho kinase inhibitor in the form of an intracameral injection or intraocular perfusion fluid.
9 . The method according to claim 2 , wherein the Rho kinase inhibitor is 1-(5-isoquinolinesulfonyl)homopiperazine or a pharmacologically acceptable salt thereof.
10 . The method according to claim 9 , comprising administering an effective amount of a Rho kinase inhibitor in the form of an intracameral injection or intraocular perfusion fluid.
11 . The method according to claim 9 , wherein the eye is a human eye.
12 . The method according to claim 11 , comprising administering an effective amount of a Rho kinase inhibitor in the form of an intracameral injection or intraocular perfusion fluid.
13 . The method according to claim 1 , wherein the corneal endothelial dysfunction caused by increased intraocular pressure comprises glaucomatous attack.
14 . The method according to claim 4 , wherein the corneal endothelial dysfunction caused by increased intraocular pressure comprises glaucomatous attack.
15 . The method according to claim 13 , wherein the eye is a human eye.
16 . The method according to claim 14 , wherein the eye is a human eye.